AKBA
Akebia Therapeutics, Inc.stockNASDAQ
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia's lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia's global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.40 | 2026-11-06 | +17.89% | 12.812 |
| 1M | 0.77 | 2026-10-13 | -38.56% | 7.409 |
| 3M | 0.87 | 2026-08-13 | -45.60% | 5.705 |
| 6M | 1.18 | 2026-05-13 | -59.91% | 3.578 |
| 1Y | 1.76 | 2025-11-13 | -73.12% | 2.483 |
| 2Y | 1.92 | 2024-11-13 | -75.36% | — |
| 5Y | 2.87 | 2021-11-12 | -83.52% | 1.578 |
Akebia Therapeutics, Inc. (NASDAQ:AKBA) stock price today is $0.47, and today's volume is 3,887,612. AKBA is down 5.000% today. The 30 day average volume is 8.79M. AKBA market cap is $131.36M with 277.66M shares outstanding.
